Greg Koch

Statistics

Publications

Citations

335

H-Index

Active since

1997

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Greg Koch is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in cell signaling, receptor-ligand interactions, and ligand binding.

Publications per year

1997–2003

Publications

Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation

Jenny Xie, Naomi Nomura, Min Lu et al. · Journal of Leukocyte Biology · 2003 · 170 citations

Life Sciences, Cell Biology, Immunology +16

Substituted Imidazoles as Glucagon Receptor Antagonists

Linda L. Chang, Kelly L. Sidler, Margaret A. Cascieri et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 108 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Alterations in Receptor Activation and Divalent Cation Activation of Agonist Binding by Deletion of Intracellular Domains of the Glucagon Receptor

Gary G. Chicchi, Michael P. Graziano, Greg Koch et al. · Journal of Biological Chemistry · 1997 · 33 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Gαi-coupled and uncoupled states

Jerry Di Salvo, Greg Koch, Kristine Johnson et al. · European Journal of Pharmacology · 2000 · 24 citations

Medicine, Molecular Biology, Pharmacology +16

1–4 of 4